Dicot Pharma
0.219
SEK
-0.68 %
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-0.68%
+4.3%
+1.16%
+9.42%
-6.58%
+71.73%
-35.67%
-76.75%
-91.45%
www.dicotpharma.com/investor-relations
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot's main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market.
Revenue
230K
EBIT %
-19,569.57 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DICOT
Daily low / high price
0.214 / 0.22
SEK
Market cap
388.66M SEK
Turnover
314.22K SEK
Volume
1.5M
Financial calendar
Annual report
13.02.2025
Interim report
29.04.2025
General meeting
06.05.2025
Interim report
12.08.2025
Interim report
23.10.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 10.5 % | 10.5 % |
| Bertil Lindkvist (Ålandsbanken) | 7.6 % | 7.6 % |
| Nordnet Pensionsförsäkring | 3.6 % | 3.6 % |
| Tor Finans AB | 3.2 % | 3.2 % |
| Torsten Söderberg med familj | 1.9 % | 1.9 % |
| Stefan Henriksson | 1.3 % | 1.3 % |
| Christian och Gerd Lentz | 1.2 % | 1.2 % |
| Klas Göran Strömberg | 1.0 % | 1.0 % |
| Michael Zell | 0.9 % | 0.9 % |
| Wilhelm Risberg | 0.9 % | 0.9 % |
ShowingAll content types
Dicot Pharma AB: First participants dosed in Dicot Pharma's Phase 2a clinical study
Dicot Pharma AB: International business development expert joins Dicot Pharma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools